RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Business Insider1d
Stifel Nicolaus Sticks to Its Buy Rating for RegenXBio (RGNX)
Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.15. Don't Miss ...
Benzinga.com2d
What's Going On With REGENXBIO Shares Monday?
REGENXBIO doses first patient in its trial for Duchenne gene therapy. The company announces positive data from Phase I/II part of AFFINITY DUCHENNE trial. REGENXBIO Inc. RGNX stock is trading ...
FierceBiotech2d
After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. After discussions with the FDA, the biotech has ...
Seeking Alpha4d
Regenxbio down 13% ahead of data readout for muscular dystrophy asset
It uses the AAV8 vector. The article has also been clarified to indicate the number of patients enrolled in the AFFINITY DUCHENNE program when Regenxbio issued interim data inb August.
STAT2d
Regenxbio says gene therapy strengthened boys with Duchenne muscular dystrophy
Regenxbio reported Monday the first clinical evidence showing improved muscle function in boys with Duchenne muscular dystrophy following treatment with its experimental gene therapy. The positive ...
Yahoo Finance6d
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 ...
Yahoo Finance2d
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
ROCKVILLE, Md., Nov. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE ®, the multi-center, open-label trial of RGX-202, a potential best-in-class gene ...
SDxCentral6d
REGENXBIO Webcast to Highlight AFFINITY DUCHENNE® Trial Data
ABOUT REGENXBIO Inc. SOURCE REGENXBIO Inc. The views, thoughts, and opinions expressed in this press release belong solely to the organization that provided the press release and do not reflect ...
Nasdaq5d
5 Analysts Have This To Say About Regenxbio
Across the recent three months, 5 analysts have shared their insights on Regenxbio (NASDAQ:RGNX), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...
Yahoo Finance6d
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days ...